Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Chief Medical Officer | April 01, 2026 | April 02, 2026 |
| OS Therapies IncOSTX · Entity 6950 | Director | July 01, 2026 | July 23, 2026 |
| Q/C TECHNOLOGIES, INC.MYMD · Entity 7735 | Director | June 07, 2023 | June 09, 2023 |
| Telomir Pharmaceuticals, Inc.TELO · Entity 6962 | Director | February 08, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date April 01, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,001 |
Ending reported balance
After 2026-04-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-04-01 · Exercise / conversion · Acquired 1,714 · Balance 68,094 Row 2 · 2026-04-01 · Exercise / conversion · Acquired 1,667 · Balance 69,761 Row 3 · 2026-04-01 · Exercise / conversion · Acquired 2,660 · Balance 72,421 Row 4 · 2026-04-01 · Exercise / conversion · Acquired 5,359 · Balance 77,780 Row 5 · 2026-04-01 · Tax withholding · Disposed 5,779 · Balance 72,001 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,429 |
Reported balance
After 2026-04-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-01 · Exercise / conversion · Disposed 1,714 · Balance 3,429 F2: This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,335 |
Reported balance
After 2026-04-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-01 · Exercise / conversion · Disposed 1,667 · Balance 3,335 F4: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,955 |
Reported balance
After 2026-04-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-01 · Exercise / conversion · Disposed 2,660 · Balance 15,955 F5: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,883 |
Reported balance
After 2026-04-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-01 · Exercise / conversion · Disposed 5,359 · Balance 10,883 F6: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F6: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
OS Therapies Inc
Report date July 01, 2026 · Filed July 23, 2026
This filing explicitly reported no securities owned.
Q/C TECHNOLOGIES, INC.
Report date June 07, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.66 · Expires 2028-06-07 | Direct | 475,000 |
Reported balance
After 2023-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Acquired 475,000 · Balance 475,000 F1: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date.
Telomir Pharmaceuticals, Inc.
Report date February 08, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 487,805 |
Reported balance
Holding disclosure · report date 2024-02-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 487,805 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2023 Filed Jun 13, 2023 21:38 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRESTRICTED STOCK UNITS · Derivative | 16,738 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000081 · wk-form4_1686692316.xml · derivative · entry 2 EAGLE CRAIG · CIK 0001562135 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,738 Underlying: COMMON STOCK · 16,738 shares Expires not disclosed F2 · derivative.exercise_date: This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vests on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:38 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 25,107 | $0.00 Strike: $32.86 | $0.00 |
DisclosureSEC source: 0001576280-23-000081 · wk-form4_1686692316.xml · derivative · entry 1 EAGLE CRAIG · CIK 0001562135 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,107 Underlying: COMMON STOCK · 25,107 shares Expires 2033-06-09 F1 · derivative.exercise_date: This represents a stock option award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vests on June 9, 2024, and the remaining 67% of the shares vests in equal installments on each monthly anniversary of June 9, 2024, during the two-year period thereafter. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 22:00 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 475,000 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001493152-23-020797 · ownership.xml · derivative · entry 1 EAGLE CRAIG · CIK 0001562135 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date. Read SEC document |
| May 15, 2023 Filed May 16, 2023 21:16 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 3,718 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000068 · wk-form4_1684271754.xml · derivative · entry 3 EAGLE CRAIG · CIK 0001562135 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,435 Underlying: COMMON STOCK · 3,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on May 15, 2022, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each anniversary of May 15, 2022, during the three-year period thereafter. F3 · derivative.expiration_date: Not applicable to Restricted Stock Units. Read SEC document |
| May 15, 2023 Filed May 16, 2023 21:16 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCOMMON STOCK | 1,286 | $27.89 | $35,866.54 |
DisclosureSEC source: 0001576280-23-000068 · wk-form4_1684271754.xml · nonDerivative · entry 2 EAGLE CRAIG · CIK 0001562135 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,863 F1 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| May 15, 2023 Filed May 16, 2023 21:16 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 3,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000068 · wk-form4_1684271754.xml · nonDerivative · entry 1 EAGLE CRAIG · CIK 0001562135 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:32 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRESTRICTED STOCK UNITS · Derivative | 27,426 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-22-000098 · wf-form4_166803311676621.xml · derivative · entry 2 EAGLE CRAIG · CIK 0001562135 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,426 Underlying: COMMON STOCK · 27,426 shares Expires not disclosed F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vests on November 7, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable to Restricted Stock Units. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:32 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 54,852 | $0.00 Strike: $47.20 | $0.00 |
DisclosureSEC source: 0001576280-22-000098 · wf-form4_166803311676621.xml · derivative · entry 1 EAGLE CRAIG · CIK 0001562135 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,852 Underlying: COMMON STOCK · 54,852 shares Expires 2032-11-06 F1 · derivative.exercise_date: This represents a stock option granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vests on November 7, 2023 and the remaining 75% of the shares vests in equal monthly installments over the remaining three-year period thereafter. Read SEC document |
| May 15, 2022 Filed Sep 8, 2022 20:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 3,717 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-22-000075 · wf-form4_166266753579265.xml · derivative · entry 3 EAGLE CRAIG · CIK 0001562135 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,153 Underlying: COMMON STOCK · 3,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on May 15, 2022, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each anniversary of May 15, 2022, during the three-year period thereafter. F3 · derivative.expiration_date: Not applicable to Restricted Stock Units. Read SEC document |
| May 15, 2022 Filed Sep 8, 2022 20:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCOMMON STOCK | 1,286 | $35.91 | $46,180.26 |
DisclosureSEC source: 0001576280-22-000075 · wf-form4_166266753579265.xml · nonDerivative · entry 2 EAGLE CRAIG · CIK 0001562135 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,431 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| May 15, 2022 Filed Sep 8, 2022 20:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 3,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-22-000075 · wf-form4_166266753579265.xml · nonDerivative · entry 1 EAGLE CRAIG · CIK 0001562135 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2021 Filed Oct 15, 2021 21:21 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-025605 · ownership.xml · derivative · entry 1 EAGLE CRAIG · CIK 0001562135 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of MyMD Pharmaceuticals, Inc. (the "Company"). F2 · derivative.exercise_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control. F2 · derivative.expiration_date: The RSUs vest as follows: (i) 33% if the Company's market capitalization equals or exceeds $500,000,000 for at least 10 trading days during any 20 consecutive trading day period ending on or after December 15, 2021 (the "Required Period") and the fair market value (the "FMV") of the common stock equals or exceeds $5.00, subject to standard adjustments (the "Minimum Share Value") during such Required Period, (ii) 33% if the Company's market capitalization equals or exceeds $750,000,000 for the Required Period at the Minimum Share Value, and (iii) the remainder if the Company's market capitalization equals or exceeds $1,000,000,000 for the Required Period at the Minimum Share Value; provided that the RSUs shall vest immediately upon the occurrence of a change in control that values the Company's common stock at least $500,000,000, provided that the Reporting Person is providing services to the Company on the closing date of such change in control. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 29,740 | $0.00 Strike: $110.49 | $0.00 |
DisclosureSEC source: 0001576280-21-000082 · wf-form4_162819833818493.xml · derivative · entry 2 EAGLE CRAIG · CIK 0001562135 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,740 Underlying: COMMON STOCK · 29,740 shares Expires 2031-08-02 F3 · derivative.exercise_date: The stock option vests as to 25% of the shares subject to such award on April 27, 2022, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of April 27, 2022, during the three-year period thereafter. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:19 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRESTRICTED STOCK UNITS · Derivative | 14,870 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-21-000082 · wf-form4_162819833818493.xml · derivative · entry 1 EAGLE CRAIG · CIK 0001562135 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,870 Underlying: COMMON STOCK · 14,870 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on May 15, 2022, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each anniversary of May 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable to Restricted Stock Units. Read SEC document |
| April 16, 2021 Filed Apr 23, 2021 01:29 UTC | Q/C TECHNOLOGIES, INC. MYMD · Entity 7735 | GrantStock Option (Right to Buy) · Derivative | 482,375 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001493152-21-009498 · ownership.xml · derivative · entry 1 EAGLE CRAIG · CIK 0001562135 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,375 Underlying: Common Stock · 482,375 shares Expires 2023-04-16 F1 · price: Received in exchange for a stock option to acquire 1,250,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share. F2 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.